General Announcement::GPL to commence Phase 3 clinical trial on a combination of antiviral drugs Favipiravir & Umifenovir

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
26-May-2020 13:34:14
Status
New
Announcement Sub Title
GPL to commence Phase 3 clinical trial on a combination of antiviral drugs Favipiravir & Umifenovir
Announcement Reference
SG200526OTHRGUGN
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
26/05/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India

Attachments

PR_SGX_26052020.pdf
Total size =941K